Business
Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2025 AACR Annual Meeting
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that preclinical data on multiple novel bispecific antibodies as well as antibody-drug-conjugates (ADCs) from its oncology pipeline will be presented at the American Association for Cancer Research (AACR) Annual Me
About this update from Innovent Biologics, Inc.
[{"type":"text","content":"SAN FRANCISCO and SUZHOU, China, March 27, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that preclinical data on multiple novel bispecific antibodies as well as antibody-drug-conjugates (ADCs) from its oncology pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025. The AACR Annual Meeting will take place from April 25 to April 30, 2025, in Chicago, Illinois.","length":680,"tagName":"p"},{"type":"text","content":"Late-Breaking Research: Immunology 2","length":36,"tagName":"p"},{"type":"text","content":"Topic: Preclinical Data of IAR037, A Novel CD40/PD-L1 Bispecific Antibody for the Treatment of Advanced Solid Tumors Resistant to Immune Checkpoint InhibitorsAbstract Number: LB139Presentation Time：Monday Apr 28, 2025 9:00 AM - 12:00 PMLocation: Poster Section 52","length":266,"tagName":"p"},{"type":"text","content":"Late-Breaking Research: Clinical Research 1","length":43,"tagName":"p"},{"type":"text","content":"Topic: Preclinical characterization of IBI3010, a FRα targeting biparatopic antibody-drug conjugate (ADC), for the treatment of FRα expressing tumorsAbstract Number: LB222Presentation Time：Monday Apr 28, 2025 2:00 PM - 5:00 PMLocation: Poster Section 53","length":256,"tagName":"p"},{"type":"text","content":"Poster Session: Experimental and Molecular Therapeutics - New and Emerging Cancer Drug Targets","length":94,"tagName":"p"},{"type":"text","content":"Topic: IBI3019, a first-in-class EGFR/CDH17/CD16A tri-specific antibody, demonstrated potent efficacy against CRC and an excellent safety profile in preclinical studiesAbstract Number: 4249Presentation Time: Tuesday Apr 29, 2025 9:00 AM - 12:00 PMLocation: Poster Section 17Poster Board Number: 6","length":315,"tagName":"p"},{"type":"text","content":"Poster Session: Experimental and Molecular Therapeutics - Therapeutic Approaches to Attack the Tumor Microenvironment","length":117,"tagName":"p"},{"type":"text","content":"Topic: IBI3026, a first-in-class anti-PD-1/IL-12 fusion protein, demonstrates the potential to be a new immuno-oncology therapy ...